ESSA Pharma Inc
EPIX0.201USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
8.93MMarket Cap
LossP/E TTM
More Details of ESSA Pharma Inc Company
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
ESSA Pharma Inc Info
Ticker SymbolEPIX
Company nameESSA Pharma Inc
IPO dateFeb 22, 2021
CEODr. David Ross Parkinson, M.D.
Number of employees35
Security typeOrdinary Share
Fiscal year-endFeb 22
Address999 West Broadway, Suite 720
CityVANCOUVER
Stock exchangeNASDAQ Capital Market Consolidated
CountryCanada
Postal codeV5Z 1K5
Phone17783310962
Websitehttps://www.essapharma.com/
Ticker SymbolEPIX
IPO dateFeb 22, 2021
CEODr. David Ross Parkinson, M.D.
Company Executives of ESSA Pharma Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jon Adkins
Mr. Jon Adkins
President, Treasurer, Secretary, Director
President, Treasurer, Secretary, Director
--
--
Mr. David Sidney Wood, CPA
Mr. David Sidney Wood, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter Virsik
Mr. Peter Virsik
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
-100.00%
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Mr. Jon Adkins
Mr. Jon Adkins
President, Treasurer, Secretary, Director
President, Treasurer, Secretary, Director
--
--
Mr. David Sidney Wood, CPA
Mr. David Sidney Wood, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter Virsik
Mr. Peter Virsik
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
-100.00%
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
-100.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Oct 17
Updated: Fri, Oct 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Xeno Acquisition Corp
100.00%
Opaleye Management Inc.
4.67%
BofA Global Research (US)
1.33%
Aldebaran Capital, LLC
1.22%
Aguja Capital GmbH
1.06%
Shareholders
Shareholders
Proportion
Xeno Acquisition Corp
100.00%
Opaleye Management Inc.
4.67%
BofA Global Research (US)
1.33%
Aldebaran Capital, LLC
1.22%
Aguja Capital GmbH
1.06%
Shareholder Types
Shareholders
Proportion
Corporation
100.00%
Research Firm
5.52%
Hedge Fund
3.75%
Investment Advisor
0.85%
Venture Capital
0.10%
Investment Advisor/Hedge Fund
0.08%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
79
34.87M
73.70%
-13.44M
2025Q2
91
32.28M
72.72%
-18.24M
2025Q1
96
33.48M
75.44%
-17.56M
2024Q4
101
34.20M
77.05%
-15.63M
2024Q3
97
36.44M
82.10%
-7.65M
2024Q2
110
36.54M
82.36%
-10.99M
2024Q1
138
36.33M
81.91%
-11.35M
2023Q4
143
35.77M
81.03%
-12.57M
2023Q3
161
36.59M
82.99%
-18.42M
2023Q2
177
36.37M
82.51%
-21.24M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Opaleye Management Inc.
2.21M
4.67%
--
--
Jun 30, 2025
BofA Global Research (US)
627.93K
1.33%
-70.34K
-10.07%
Jun 30, 2025
Aldebaran Capital, LLC
578.94K
1.22%
+9.64K
+1.69%
Jun 30, 2025
Aguja Capital GmbH
500.00K
1.06%
--
--
Apr 30, 2025
Two Sigma Investments, LP
483.13K
1.02%
-72.09K
-12.98%
Jun 30, 2025
DLD Asset Management, LP
314.97K
0.67%
+131.31K
+71.50%
Jun 30, 2025
BNP Paribas Securities Corp. North America
271.19K
0.57%
+35.79K
+15.21%
Jun 30, 2025
LMR Partners LLP
200.00K
0.42%
+200.00K
--
Jun 30, 2025
J.P. Morgan Securities LLC
189.07K
0.4%
+24.22K
+14.69%
Jun 30, 2025
View more
Related ETFs
Updated: Mon, Oct 6
Updated: Mon, Oct 6
Name
Proportion
Avantis US Small Cap Equity ETF
0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of ESSA Pharma Inc?
The top five shareholders of ESSA Pharma Inc are:
Opaleye Management Inc. holds 2.21M shares, accounting for 4.67% of the total shares.
BofA Global Research (US) holds 627.93K shares, accounting for 1.33% of the total shares.
Aldebaran Capital, LLC holds 578.94K shares, accounting for 1.22% of the total shares.
Aguja Capital GmbH holds 500.00K shares, accounting for 1.06% of the total shares.
Two Sigma Investments, LP holds 483.13K shares, accounting for 1.02% of the total shares.
Opaleye Management Inc. holds 2.21M shares, accounting for 4.67% of the total shares.
BofA Global Research (US) holds 627.93K shares, accounting for 1.33% of the total shares.
Aldebaran Capital, LLC holds 578.94K shares, accounting for 1.22% of the total shares.
Aguja Capital GmbH holds 500.00K shares, accounting for 1.06% of the total shares.
Two Sigma Investments, LP holds 483.13K shares, accounting for 1.02% of the total shares.
What are the top three shareholder types of ESSA Pharma Inc?
The top three shareholder types of ESSA Pharma Inc are:
Xeno Acquisition Corp
Opaleye Management Inc.
BofA Global Research (US)
Xeno Acquisition Corp
Opaleye Management Inc.
BofA Global Research (US)
How many institutions hold shares of ESSA Pharma Inc (EPIX)?
As of 2025Q3, 79 institutions hold shares of ESSA Pharma Inc, with a combined market value of approximately 34.87M, accounting for 73.70% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 0.98%.
What is the biggest source of revenue for ESSA Pharma Inc?
In --, the -- business generated the highest revenue for ESSA Pharma Inc, amounting to -- and accounting for --% of total revenue.
